Vivo Capital and Food and Drug Administration

Selected healthcare news for the capital firm - Vivo Capital, and the healthcare topic - Food and Drug Administration. We have 13 shared news items for this connection to-date. Based on the volume of shared news, it's source, placement and other factors, this connection is scored as strong.  Vivo Capital shares healthcare news with Preventice, Preventice Solutions, Biotech, OrbiMed and dozens of others. Food and Drug Administration shares news with COVID-19, Donald Trump, CDC, Pfizer, Department of Health and Human Services and hundreds of others.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/10/2020 Terns Pharmaceuticals Receives Fast Track Designation for TERN-201 as a Treatment for NASH | Business & Finance | manchestertimes.com Business Wire ... announced that TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of non-alcoholic steatohepatitis (NASH). Terns recently ... small molecule GLP-1R agonist program. Terns’ investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital. For more information, visit www.ternspharma.com and www.ternspharma.com.cn View source version on businesswire.com : https://www.businesswire.com/news/home/20200910005090 ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/12/2020 Investors just poured $14.6 billion into startups working to transform healthcare. These are the 10 companies that pulled in the most cash. Business Insider ... Series A funding from investors including Hudson Bay Capital Management, Johnson & Johnson Innovation, Lilly Asia Ventures, RA Capital Management, and Vivo Capital, according to a recent announcement . It plans to spend the funds on research ... treatment recently won an expedited approval process from the US Food and Drug Administration, according to the companies . Concerto HealthAI - $150 million Concerto employees are seen in Boston. Concerto HealthAI Concerto HealthAI specializes in machine ...
5/9/2020 venBio closes third fund for biopharma startup investment, valued at $394M MedCity News ... company that is developing drugs that target the CD47 immune checkpoint; venBio, an existing investor, participated in that round, which Vivo Capital led. In early January, venBio led a $40 million Series B financing round ... venBio portfolio company was Harmony Bioscience’s Wakix (pitolisant), which the Food and Drug Administration approved in August for treating adult patients with narcolepsy. “We remain committed to our founding strategy at venBio, namely to turn ...
11/26/2019 Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors PR Newswire ... a BComm and an LL.B. from the University of Alberta . Gaurav Aggarwal , M.D., has served as a Managing Director of Vivo Capital LLC, a healthcare focused investment firm, since October 2016 , where he focuses on ... have been treated previously with a JAK inhibitor. The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received ...
11/26/2019 Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors Yahoo News ... a BComm and an LL.B. from the University of Alberta . Gaurav Aggarwal , M.D., has served as a Managing Director of Vivo Capital LLC, a healthcare focused investment firm, since October 2016 , where he focuses on ... have been treated previously with a JAK inhibitor. The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received ...
1/17/2018 Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA PR Newswire ... a biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted two Investigational New Drug (IND) applications for its ... Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital and Takeda Ventures. For more information, visit Outpost's website at www.outpostmedicine.com . Contact ...
1/17/2018 Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by PR Newswire ... a biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted two Investigational New Drug (IND) applications for its ... Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital and Takeda Ventures. For more information, visit Outpost's website at www.outpostmedicine.com . Contact: Theresa Owens Targeted Communications [email protected] +1-317-983-4476 View original content with ...